A Dkk1 vaccination study in a murine model of myeloma showed higher CD4+ and CD8+ T-cell immune activity and provided a strong rationale for using Dkk1 as a myeloma immunotherapeutic target [141]. The gene discussed is CD8A; the disease is plasma cell myeloma.